

Anti-tumor effect of Compound A in H716 xenograft model
Tumor Volume (mm3)
4000
3600
3200
2800
2400
2000
1600
1200
800
400
0
Vehicle
Compound A - 20 mg/kg Bid
Compound A - 40 mg/kg Bid
Compound A - 80 mg/kg Bid
days of treatment

Figure 1



PK profiles of Capsule A in Beagle dogs following a single oral dose (30 mg/kg) in period 1
Plasma Concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
1_Male
2_Male
3_Male
4_Female
5_Female
6_Female

Figure 2



PK profiles of Capsule B in Beagle dogs following a single oral dose (30 mg/kg) in period 2
Plasma Concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
1_Male
2_Male
3_Male (vomit at 45 min)
4_Female (vomit at 10 min)
5_Female (vomit at 2 min)
6_Female (vomit at 40 min)

Figure 3



PK profiles of Capsule B in Beagle dogs following a single oral dose (30 mg/kg) in period 1
Plasma Concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time (h)
7_Male (vomit at 1.5 hrs)
8_Male (Vomit at 20 min)
9_Male
10_Female
11_Female
12_Female

Figure 4



PK profiles of Capsule A in Beagle dogs following a single oral dose (30 mg/kg) in period 2
7_Male
8_Male
9_Male
10_Female (vomit at 25 min)
11_Female
12_Female
Plasma Concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time (h)

Figure 5



mean concentration-time profile of Compound A in Beagle dog plasma after single PO dosing of Capsule A and Capsule B
Capsule A
Capsule B
Plasma concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time (h)

Figure 6




Figure 7




Figure 8